Soda giants have exploited the world’s most popular sport for commercial gain, and FIFA has an opportunity to lead by example by dropping them as sponsors of the 2025 Club World Cup, write Chris van Tulleken and Carlos A Monteiro During the 2022 FIFA World Cup in Qatar, one name dominated the field—and it wasn’t a player. Coca-Cola was ubiquitous,1 appearing on massive billboards, in halftime commercials, and in the hands of athletes during press conferences. This extended beyond conventional advertising: it represented a calculated corporate strategy, illustrating the extent to which sponsorships have integrated unhealthy products into the structure of professional sport. As the 2025 FIFA Club World Cup begins, we as doctors and public health advocates have a duty to call out Coca-Cola and other sugary drink companies that have entrenched themselves in the world of sports through marketing—profiting off players and fans while contributing to a global health crisis. We need to hold …

More awareness, research, and treatments are needed The rise in non-prescribed use of ketamine across the UK in recent years is concerning because of the potential effects on physical and mental wellbeing and overall quality of life. Despite its classification as a class B drug under the Misuse of Drugs Act 1971, public awareness of the risks and long term harms associated with ketamine remains insufficient. Ketamine is used clinically as a general anaesthetic, with subanaesthetic doses prescribed for chronic pain, treatment resistant depression, and suicidality.1 Recent studies have shown promise for its use in the treatment of post-traumatic stress disorder and opioid and alcohol dependence.2 Although intranasal esketamine is licensed for treatment of depression, it is not approved by the National Institute for Health and Care Excellence. Generic racemic ketamine is often used as a cheaper off-label alternative. However, ketamine is increasingly used recreationally at individual dose

Objective To assess the risk of intracranial meningioma associated with oral contraceptives containing desogestrel, levonorgestrel, or levonorgestrel combined with oestrogen. Design Case-control study. Setting French national health data system (Système National des Données de Santé). Participants 8391 women living in France who required surgery for intracranial meningioma in 2020-23. Each patient was matched to 10 women without intracranial meningioma (controls) on year of birth and area of residence. Main outcome measure Risk of intracranial meningioma associated with oral contraceptives containing desogestrel 75µg, levonorgestrel 30µg, or levonorgestrel 50-150 µg combined with oestrogen, and duration of use: short term use was defined by one or more dispensations within the year before the index date only, and prolonged use was defined by continuous use of one year or more (up to seven or more years of continuous use). Conditional logistic regression was used to calculate odds ratio